Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real −world retrospective study
ConclusionNeoadjuvant PD-1 inhibitors combined with chemotherapy are feasible and safe, with a high pathological response and possible organ preservation in oral or oropharyngeal squamous cell carcinoma. However, further studies with a larger cohort of patients and longer follow-up period is required to strengthen our findings and evaluate the survival benefits of the treatment.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Abraxane | Allergy & Immunology | Alopecia | Anorexia | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Eating Disorders & Weight Management | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Oral Cancer | Oropharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Study